Linked Life Data

12585303

Source:http://linkedlifedata.com/resource/pubmed/id/12585303

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-2-13
pubmed:abstractText
Despite the importance of patient insurance in the market for prescription pharmaceuticals, little is known about the impact of patient reimbursement on the pricing behavior of pharmaceutical firms. I examine the link between potential patient out-of-pocket expenses and pharmaceutical pricing using a unique policy experiment from Germany. Starting in 1989, a maximum reimbursement for a given medicine replaced a flat prescription fee. This change in reimbursement exposes the patient to the price of a prescribed product. Using a product-level panel data set covering several therapeutic categories before and after the policy change, I find that producers significantly decrease prices after the change in potential patient out-of-pocket expenses. Price declines are most pronounced for brand-name products. Moreover, branded products that face more generic competitors reduce prices more.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
T
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0741-6261
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
HSR
pubmed:authorsComplete
Y
pubmed:pagination
469-87
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
pubmed:affiliation
Dartmouth College, USA. nina.pavcnik@dartmouth.edu
pubmed:publicationType
Journal Article